1. Introduction
===============

*Siegesbeckia glabrescens* Makino (Compositae) is an annual herb that has been used as a Chinese medicine to treat inflammatory disease, asthma, paralysis and allergic disorders \[[@B1-molecules-20-02850]\]. Flavonoids \[[@B1-molecules-20-02850]\], sesquiterpene \[[@B2-molecules-20-02850]\] and kaurane diterpenes \[[@B3-molecules-20-02850]\] have been isolated from this plant in previous phytochemical studies. It has been reported that the extracts of *S. glabrescens* exhibit antioxidative, anti-inflammatory \[[@B1-molecules-20-02850]\], antiallergic \[[@B4-molecules-20-02850]\], antibacterial \[[@B5-molecules-20-02850]\] and anti-tumor activities \[[@B6-molecules-20-02850],[@B7-molecules-20-02850]\]. In our screening program to discover new antitumor agents from medicinal herbs, two new compounds **1**--**2** and two known sesquiterpenes **3**--**4** were isolated from the ethyl acetate (EtOAc)-soluble fraction of the methanolic extract of *S. glabrescens* by chromatographic procedures. In this study, we present the structural elucidation of these two new compounds, as well as their cytotoxic activities against several human cancer cell lines including MCF-7, AsPC-1, SW480, HCT 116, HepG2 and HeLa.

2. Results and Discussion
=========================

Dried *S. glabrescens* was extracted with methanol. The crude methanol extract was subjected to liquid-liquid partition as well as a combination of several column chromatography steps to yield two new sesquiterpenoids **1** and **2** together with two known sesquiterepnoids **3** and **4** ([Figure 1](#molecules-20-02850-f001){ref-type="fig"}).

![Chemical structures of compounds **1**--**4** and key HMBC (→) and NOESY (bold ↔) correlations for compound **1**.](molecules-20-02850-g001){#molecules-20-02850-f001}

Compound **1** was obtained as an amorphous solid. The HREIMS spectrum suggested a molecular formula of **1** as C~21~H~26~O~7~. The ^13^C-NMR, DEPT, and HSQC spectra showed twenty-one carbon signals including three carbonyl carbons, eight olefinic carbons, three methylene carbons, four methine carbons, one methoxyl and two methyl groups. In ^1^H-^1^H COSY spectrum, H-4 (δ 5.26) correlated with H-3 (δ 2.82) and H-5 (δ 5.09), and also H~2~-8 (δ 2.62\~2.73) correlated with methylene protons of H~2~-7 (δ 2.06 and 2.78) and H-9 (δ 6.97). This data suggested that this compound has AMX and A~2~M~2~X spin systems. In HMBC spectrum, oxy-methylene protons H~2~-12 (δ 4.36 and δ 4.39) correlated with C-5 (δ 129.4), C-6 (δ 142.3) and C-7 (δ 33.3), and H-3 (δ 2.82) correlated with C-9 (δ 159.7) and C-10 (δ 141.5) ([Figure 1](#molecules-20-02850-f001){ref-type="fig"} and [Table 1](#molecules-20-02850-t001){ref-type="table"}). These data indicated that compound **1** has eight-membered ring in the structure with two double bonds. The correlation between terminal methylene H~2~-11 (δ 5.75 and 6.15) and a carbonyl carbon C-1 (δ 171.2) and C-3 (δ 51.9) in HMBC indicated that compound **1** is a bicycle \[6.3.0\]-γ-lactone having an exocyclic double bond in lactone ring. We also found the HMBC correlations between oxy-methine H-4 and C-6, and between H-5 and C-3. In ^1^H-^1^H COSY spectrum, we found another AMX spin system from the correlations of H-14 (δ 3.94) with H-13 (δ 6.63) and H-15 (δ 9.43). From the coupling constant of H-15 (*J* = 2.0 Hz) and chemical shift of C-15 (δ 196.8) and the HMBC correlations between H-15 (δ 9.43) and C-14 (δ 79.4), we identified the presence of an aldehyde group that is linked to C-14. In HMBC spectrum, we also found correlation between a methoxyl protons (δ 3.10) and C-14 (δ 79.4), and correlation between H-13 (δ 6.63) and C-3 (δ 51.9). The long range allylic coupling was observed between H-13 (dd, 8.4, 1.2 Hz) and H-9. These results indicated that an oxy-carbon C-13 is linked to the eight-membered ring at C-10. From the coupling constant between H-3 and H-4 (*J =*10.0 Hz,) we postulated the configurations of H-3 and H-4 based on Karplus relationship and the reported values of several bicycle \[6.3.0\]-γ-lactone derivatives ([Figure 1](#molecules-20-02850-f001){ref-type="fig"} and [Table 1](#molecules-20-02850-t001){ref-type="table"}) \[[@B8-molecules-20-02850]\]. Furthermore, the presence of 2-methylbut-2-enoyl group was recognized by ^1^H-^1^H COSY correlation of an olefinic methine H-3\' (δ 6.10) with methyl protons (δ 1.93) and the HMBC correlations of methyl protons (δ 1.88) with C-2\' (δ 128.9) and C-1\' (δ 168.4), and the correlations of methyl protons (δ 1.93) with C-2\' (δ 128.9) and C-3\' (δ 138.9). The HMBC correlation of an oxy-proton H-13 with carbonyl ester C-1\' confirmed the esterification of 2-methylbut-2-enoyl group at C-13. We found NOESY correlations of H-13 (δ 6.63) with H-3 (δ 2.82) and H-11a (δ 6.15) that indicates the orientation of H-13 as β that is located close to H-3 and H-11a. NOESY correlations was also observed between H-9 (δ 6.97) and H-15 (δ 9.43) implying the orientation of methoxyl group as β. This orientation was confirmed by the coupling constant between H-13 and H-14 as 8.2 Hz. Thus, compound **1** was identified as 2-methylbut-2-enoic acid 1-(8-hydroxymethyl-3-methylene-2-oxo-2,3,3a,6,9a-hexahydro-cycloocta\[b\]furan-4-yl)-2-methoxy-3-oxo-propyl ester. This structure is new and we named compound **1** as siegenolide A.

Compound **2** was obtained as an amorphous solid. The HREIMS spectrum suggested a molecular formula as C~20~H~24~O~7~. The ^13^C-NMR, DEPT, and HSQC spectra showed similar signals as those of compound **1** except showing one terminal olefinic methylene signals of H~2~-3\' (δ 5.65, 6.14) instead of the methyl protons (H~3~-4\') of compound **1**. The relative stereochemistry of compound **2** was determined by the analysis of NOESY spectra and coupling constants, which was same as compound **1**. Thus, the structure of compound **2** was determined as 2-methyl-acrylic acid 1-(8-hydroxymethyl-3-methylene-2-oxo-2,3,3a,6,9a-hexahydro-cycloocta\[b\]furan-4-yl)-2-methoxy-3-oxo-propyl ester, which was a new structure and named as siegenolide B.

Compounds **3** and **4** were identified as 2-methylbut-2-enoic acid,2,3,3a,4,5,8,9,10,11,11a-decahydro-6,10-bis(hydroxymethyl)-3-methylene-2-oxocyclodeca\[b\]furan-4-yl ester (**3**) and 2-methylacrylic acid, 2,3,3a,4,5,8,9,10,11,11a-decahydro-6,10-bis(hydroxymethyl)-3-methylene-2-oxocyclodeca\[b\]-furan-4-yl ester (**4**), respectively, by comparison with the reported spectral data ([Figure 1](#molecules-20-02850-f001){ref-type="fig"}) \[[@B2-molecules-20-02850],[@B9-molecules-20-02850]\].

The four sesquiterpenoids **1**--**4** were evaluated for their cytotoxic activity on human cancer cell lines such as MCF-7, AsPC-1, SW480, HCT 116, HepG2 and HeLa cells. Compounds **1**--**4** showed differential cytotoxic effects on these cancer cell lines ([Table 2](#molecules-20-02850-t002){ref-type="table"}). All of them showed significant cytotoxicity against SW480 cell line, with IC~50~ values of 1.8, 0.9, 5.2 and 3.8 μM, respectively. The cytotoxicity of compounds **3** and **4** against AsPC-1 cells was more potent (IC~50~ values of 7.3 and 4.9 μM, respectively) than that of compounds **1** and **2** (IC~50~ values 14.5 and 12.1 μM, respectively).
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###### 

NMR Spectroscopic data (400 MHz, CD~3~OD) for siegenolides A (**1**) and B (**2**).

  Position    Siegenolide A (1)   Siegenolide B (2)                                                
  ----------- ------------------- ---------------------- ---------- ------- ---------------------- ----------
  1           171.2                                                 171.3                          
              136.8                                                 136.7                          
  3           51.9                2.82, m                9, 10      52.0    2.83, m                9
  4           75.7                5.26, t (10.0)         6          75.7    5.33, t (10.0)         
  5           129.4               5.09, d (10.0)         3          129.5   5.09, d (10.0)         7, 12
  6           142.3                                                 142.2                          
  7a          33.3                2.78, m                           33.5    2.78, m                
  7b                              2.06, td (12.4, 2.0)                      2.06, td (12.4, 2.0)   
  8           28.4                2.62\~2.73, m                     28.5    2.74\~2.68, m          
  9           159.7               6.97, dd (10.4, 7.6)              159.6   6.97, dd (10.4, 7.6)   
  10          141.5                                                 141.6                          
  11a         121.5               6.15, d (3.2)          1, 3       121.4   6.13, d (3.2)          1, 3
  11b                             5.75, d (3.2)          1, 3               5.73, d (3.2)          1
  12a         60.8                4.39, brd (13.2)       5, 6, 7    61.0    4.39, brd (13.2)       5, 6, 7
  12b                             4.36, brd (13.2)       5, 6, 7            4.33, brd (13.2)       5, 6, 7
  13          70.6                6.63, dd (8.4, 1.2)    3, 1\'     71.6    6.56, dd (8.4, 1.6)    1\'
  14          79.4                3.94, dd (8.4, 2.0)               79.4    3.92, dd (8.4, 2.0)    15
  15          196.8               9.43, d (2.0)          14         196.8   9.44, d (2.0)          14
  1\'         168.4                                                 167.7                          
  2\'         128.9                                                 137.4                          
  3\'         138.9               6.10, m                           126.8   5.65, dd (3.2, 1.6)    
                                                                            6.14, dd (3.2, 1.6)    
  14-OCH~3~   56.9                3.10, s                14         57.0    3.09, s                14
  2\'-Me      20.7                1.88, pentet (1.6)     1\', 2\'   18.5    1.94, brs              1\', 2\'
  3\'-Me      15.9                1.93, dq (7.2, 1.6)    2\', 3\'                                  

Note: *^a^* HMBC correlations start from proton(s) to the indicated carbon.

molecules-20-02850-t002_Table 2

###### 

Cytotoxicity of compounds **1**--**4** against cancer cell lines.

  Compounds       IC~50~ (μM)                                                      
  --------------- ------------- ------------ ----------- ------------ ------------ ------------
  **1**           9.5 ± 0.3     14.5 ± 0.9   1.8 ± 0.1   5.9 ± 0.2    20.2 ± 1.1   33.3 ± 2.3
  **2**           8.7 ± 0.4     12.1 ± 0.2   0.9 ± 0.1   3.2 ± 0.3    9.9 ± 0.4    23.9 ± 1.2
  **3**           9.7 ± 0.7     7.3 ± 0.5    5.2 ± 0.4   9.2 ± 0.6    14.4 ± 1.0   12.3 ± 0.7
  **4**           12.7 ± 0.7    4.9 ± 0.2    3.8 ± 0.1   11.4 ± 0.8   27.8 ± 1.4   24.7 ± 0.9
  **cisplatin**   13.0 ± 0.6    2.3 ± 0.2    4.8 ± 0.4   3.6 ± 0.1    5.9 ± 0.7    0.89 ± 0.1

Against HCT116 and HepG2 cells, compound **2** showed relatively high cytotoxicity, and against MCF-7 cells all compounds showed moderate cytotoxicity. All of these compounds displayed weak cytotoxicity against HeLa cells, with IC~50~ values (12.3--33.3 μM) compared to that of cisplatin (0.9 μM). Cytotoxicity of sesquiterpenes with α, β-unsaturated lactone structure was well known. Compounds **1** and **2** are uncommon sesquiterpenoids with eight-membered ring and they also showed same type of cytotoxicity as reported \[[@B10-molecules-20-02850]\].

3. Experimental Section
=======================

3.1. General Experimental Procedures
------------------------------------

UV spectra were recorded using an Ultraspec 4000 double beam spectrophotometer (Pharmacia Biotech, Cambridge, UK). 1D- and 2D-NMR spectra were obtained on a UNITY INOVA 400 spectrometer (Varian, Palo Alto, CA, USA). Mass spectra were determined on a JMS-AX505WA mass spectrometer (JEOL, Tokyo, Japan). Column chromatography was carried out over silica gel (40--60 μm, Merck, Merck, Kenilworth, NJ, USA), LiChroprep RP-C18 (40--60 μm, Merck) and µ-Bondapak C~18~ column (10 μm, 10 i.d. × 300 mm) (Waters Co., Milford, MA, USA). Fractions obtained from column chromatography were monitored by thin layer chromatography (TLC) (RP-C18 F~254S~ and silica gel 60 F~254~, Merck).

3.2. Plant Material
-------------------

The whole plant of *Siegesbeckia glabrescens* Makino (Compositae) was collected from Wan-Do, Jeolla-Namdo Province, Korea in November 2005 and authenticated by Prof. K. S. Yang at the College of Pharmacy, Sookmyung Women's University (SMU). A voucher specimen (No. SPH 2005007) was deposited in the herbarium of SMU.

3.3. Extraction and Isolation
-----------------------------

The air-dried material (5 kg) was reflux extracted with methanol (6 × 2 L) to yield after solvent removal a crude methanol extract (578 g), which was successively partitioned twice with EtOAc (3 L) and H~2~O (3 L). The EtOAc soluble fraction (368 g) was subjected to silica gel column chromatography (CC) (13 × 26 cm, 0.063--0.2 mm) eluting with a gradient mixture of CHCl~3~--MeOH (100:1, 70:1, 30:1, 20:1, 12:1, 5:1; 2 L each) to give 26 fractions. Fraction 9 (45 g, V~R~ 5.5--6.0 L) was further fractionated by silica gel column with a gradient elution of CHCl~3~--MeOH (40:1 to 36:1, 2 L each) to afford Fr. 9-4 (3.4 g, V~R~ 1.2--1.6 L). Fr. 9-4 was subjected to an ODS column (5 × 8 cm, 0.040--0.063 mm) eluting with MeOH--H~2~O (1:1) to afford cytotoxic Fr. 9-4-1 (400 mg, V~R~ 1.2--1.4 L) which was subjected to Sephadex LH-20 CC (0.018--0.111 mm) eluted with 70% MeOH to yield pure compound **1** (18 mg, V~R~ 230--290 mL). Fr. 9-4-1-1 (113.6 mg) was subjected to ODS column chromatography eluting with MeOH--H~2~O (1:1.6) to yield compound **2** (11.2 mg, V~R~ 80--120 mL). Fr. 11 (4.0 g, V~R~ 9.1--10.8 L) was separated by a silica gel column chromatography eluting with CHCl~3~--MeOH (40:1) to obtain cytotoxic Fr. 11-9 (234 mg, V~R~ 2.8--3.2 L). Fr. 11-9 (234 mg) was purified by ODS column chromatography eluting with MeOH--H~2~O (1:3) to yield compounds **3** (40 mg, V~R~ 120--145 mL) and **4** (11 mg, V~R~ 210--240 mL). The purities of compounds **1**--**4** were higher than 95% as confirmed by HPLC chromatogram and ^1^H-NMR spectra.

Compound **1**: amorphous solid; $\left\lbrack \alpha \right\rbrack_{D}^{24}$: −96.4, (c 0.005, MeOH), UV (MeOH) λ~max~ (log ε) 244 (3.11), 235 (3.10) nm; IR (CaF~2~, cm^−1^) 3476, 2925, 1764, 1720, 1686. ^1^H- and ^13^C-NMR data, see [Table 1](#molecules-20-02850-t001){ref-type="table"}; HREIMS *m/z* 390.1685 \[M\]^+^ (calcd for C~21~H~26~O~7~, 390.1678); EIMS *m/z* 390 \[M\]^+^.

Compound **2**: amorphous solid; $\left\lbrack \alpha \right\rbrack_{D}^{27}$: −5.7, (c 0.006, MeOH), UV (MeOH) λ~max~ (log ε) 253 (3.20), 245 (3.18) nm; IR (CaF~2~, cm^−1^) 3500, 2931, 1766, 1722, 1686, 1157. ^1^H- and ^13^C-NMR data, see [Table 1](#molecules-20-02850-t001){ref-type="table"}; HREIMS *m/z* 376.1518 \[M\]^+^ (calcd for C~20~H~24~O~7~, 376.1522); EIMS *m/z* 376 \[M\]^+^.

3.4. Cytotoxicity Assay
-----------------------

The cytotoxicity of compounds **1**--**4** against human breast cancer (MCF-7), pancreatic cancer (AsPC-1), colon cancers (SW480 and HCT 116), hepatoma (HepG2), and cervical carcinoma (HeLa) were assessed by the MTT method \[[@B11-molecules-20-02850]\]. Cells were plated at a density of 3000 cells/well in a 96 well plate. Cells were incubated with various concentrations of compounds **1**--**4** for 3 days, and then treated with MTT (5 mg/mL) solution for 4 h and lysed with DMSO. Absorbance at 540 nm was measured by using a microplate reader (Molecular Devices, Sunnyvale, CA, USA). Cisplatin (purity \> 98%) (Sigma, St. Louis, MO, USA) was used as a positive control.
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*Sample Availability*: Samples of the compounds **2** and **4** are available from the authors.

EIMS, HREIMS, ^1^H-NMR, ^13^C-NMR, DEPT, COSY, HMBC, and NOESY spectra of compounds **1** and **2** are available as supporting information. Supplementary materials can be accessed at: <http://www.mdpi.com/1420-3049/20/02/2850/s1>.

###### 

Click here for additional data file.
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